ALB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Albemarle's average Accounts Payable for the three months ended in Sep. 2024 was $1,105 Mil. Albemarle's Cost of Goods Sold for the three months ended in Sep. 2024 was $1,459 Mil. Hence, Albemarle's Days Payable for the three months ended in Sep. 2024 was 69.11.
The historical rank and industry rank for Albemarle's Days Payable or its related term are showing as below:
During the past 13 years, Albemarle's highest Days Payable was 91.74. The lowest was 43.74. And the median was 73.04.
Albemarle's Days Payable declined from Sep. 2023 (76.30) to Sep. 2024 (69.11). It may suggest that Albemarle accelerated paying its suppliers.
The historical data trend for Albemarle's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albemarle Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Payable | Get a 7-Day Free Trial | 85.84 | 90.42 | 84.88 | 91.74 | 66.48 |
Albemarle Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Payable | Get a 7-Day Free Trial | 76.30 | 49.95 | 93.33 | 72.98 | 69.11 |
For the Specialty Chemicals subindustry, Albemarle's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Chemicals industry and Basic Materials sector, Albemarle's Days Payable distribution charts can be found below:
* The bar in red indicates where Albemarle's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Albemarle's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as
Days Payable (A: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2022 ) | + | Accounts Payable (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (1533.624 | + | 1537.859) | / | 2 ) | / | 8431.294 | * | 365 |
= | 1535.7415 | / | 8431.294 | * | 365 | ||||
= | 66.48 |
Albemarle's Days Payable for the quarter that ended in Sep. 2024 is calculated as:
Days Payable (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Jun. 2024 ) | + | Accounts Payable (Q: Sep. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | ( (1138.975 | + | 1070.717) | / | 2 ) | / | 1458.726 | * | 365 / 4 |
= | 1104.846 | / | 1458.726 | * | 365 / 4 | ||||
= | 69.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Albemarle's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Netha N. Johnson | officer: President, Bromine Specialties | 3489 CRESTMOOR DRIVE, WOODBURY MN 55125 |
Barichivich John Clarence Iii | officer: VP, Controller & CAO | 4250 CONGRESS ST., SUITE 900, CHARLOTTE NC 28209 |
Kristin M Coleman | officer: EVP, General Counsel | 140 HAZEL AVE., GLENCOE IL 60022 |
Neal Ravi Sheorey | officer: Chief Financial Officer | 4250 CONGRESS STREET, SUITE 900, CHARLOTTE NC 28209 |
Michael James Simmons | officer: President - Ketjen | 301 COMMERCE STREET, SUITE 3200, FORT WORTH TX 76102 |
Eric Norris | officer: President, Lithium | 1519 AUDUBON ROAD, CHARLOTTE NC 28211 |
J Kent Masters | director | ALBEMARLE CORP., 451 FLORIDA ST, BATON ROUGE LA 70801 |
Sean B. O'hollaren | officer: Chief External Affairs Officer | 4250 CONGRESS STREET, SUITE 900, CHARLOTTE NC 28209 |
Jacobus G. Fourie | officer: Chief Capital Projects Officer | 4250 CONGRESS STREET, SUITE 900, CHARLOTTE NC 28209 |
Scott Tozier | officer: EVP & CFO | ALBEMARLE CORP, 4250 CONGRESS ST STE 900, CHARLOTTE NC 28209 |
Karen G Narwold | officer: EVP, Chief Admin Officer | ALBEMARLE CORPORATION, 4250 CONGRESS ST, SUITE 900, CHARLOTTE NC 28209 |
Raphael Goszcz Crawford | officer: President, Catalysts | 4311 GREENBRIAR HILLS PLANTATION RD, CHARLOTTE NC 28277 |
Ralf Hans Cramer | director | MIERENDORSFSTRASSE 26, BENSHEIM 2M 64625 |
Kissam Luther C Iv | director, officer: Chairman, President & CEO | 3801 BERESFORD ROAD, CHARLOTTE NC 28211 |
Melissa H. Anderson | officer: SVP, Chief HR Officer | ALBEMARLE CORPORATION, 4250 CONGRESS ST. SUITE 900, CHARLOTTE NC 28209 |
From GuruFocus
By GuruFocus News • 11-08-2024
By GuruFocus News • 10-04-2024
By GuruFocus News • 12-02-2024
By GuruFocus News • 11-21-2024
By GuruFocus News • 11-19-2024
By GuruFocus News • 10-28-2024
By GuruFocus News • 12-06-2024
By GuruFocus News • 10-31-2024
By PRNewswire • 10-28-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.